Consistent with these results, pharmacological (EGCG administration) or genetic (shRNA injection) strategies targeting Dyrk1A have been shown to abolish the proliferation and differentiation defects in iPSCs derived from an individual with DS [71]. This evidence concerns the gene DYRK1A and Dravet syndrome.